(ZLAB) Zai Lab - Ratings and Ratios

Zai Lab Limited (NASDAQ:ZLAB) is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies for unmet medical needs across oncology, immunology, neuroscience, and infectious diseases. Its commercial portfolio includes targeted cancer therapies such as Zejula (niraparib) for ovarian cancer and Qinlock (ripretinib) for gastrointestinal stromal tumors, as well as treatments for rare neurological disorders like VYVGART (efgartigimod alfa-fcab) for generalized myasthenia gravis. The company also offers antimicrobial solutions, including NUZYRA (omadacycline) for bacterial infections and Xacduro (sulbactam-durlobactam) for hospital-acquired pneumonia caused by resistant pathogens. Additionally, Zai Lab markets Optune, a tumor treating fields therapy for glioblastoma multiforme, and Augtyro (futibatinib) for non-small cell lung cancer.

The companys pipeline spans multiple therapeutic areas, with late-stage oncology assets such as bemarituzumab (anti-FGFR2b mAb) for non-small cell lung cancer and tisotumab vedotin (tisotumab vedotin-tftv) for cervical cancer. In immunology and neuroscience, Zai Lab is advancing efgartigimod alfa-fcab for chronic inflammatory demyelinating polyneuropathy and xanomeline-trospium chloride for schizophrenia and Alzheimer’s disease. Strategic collaborations with global biopharma leaders like NovoCure, argenx, Amgen, and Pfizer underscore its commitment to innovation and access to cutting-edge technologies.

Zai Lab has established a robust commercial infrastructure in China, leveraging its partnerships to bring global therapies to patients in emerging markets. Its focus on precision medicine, rare diseases, and antimicrobial resistance positions it as a key player in the global biopharmaceutical industry. Incorporated in 2013 and headquartered in Shanghai, Zai Lab has built a reputation for rapid execution and a patient-centric approach.